Kane Biotech Receives Decisions to Grant for Two European Patents Providing Broad Protection of coactiv+™ Technology for Wound Care, Skin Infections and Personal Care Formulations
WINNIPEG, Manitoba, July 29, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. announces that it has received two Decisions to Grant from the European Patent Office for patents covering its best-in-class coactiv+™ technology. The allowed claims cover composition of matter for the company's proprietary formulations for use in treating wounds and skin infections and in personal care formulations.
A “Decision to Grant” is the European Examiner’s confirmation that the European Patent Office has decided to grant Kane the patent and has set the grant date.
"These patents are important additions to the existing portfolio covering Kane’s coactiv+™ technology platform," said Gordon Guay, the company's Chief Scientific Officer. "Kane already had strong patent coverage in Europe, and the coverage of the coactiv+™ technology is now significantly enhanced, both in terms of the scope of protection, and term of protection."
Marc Edwards, CEO of Kane Biotech added: “The versatility of our coactiv+™ technology, as in our existing shampoo, pet water additive and wound gel applications, offers a pipeline of commercialization opportunities to licence, partner or go direct to market with innovative applications to treat problems caused by biofilm proliferation.”
Kane Biotech’s patented coactiv+™ is a continuously active technology specifically formulated to destabilize biofilms in order to promote an environment for fast wound healing. The key ingredients are recognized as safe by the US Food and Drug Administration and have been purposefully selected to provide support throughout the entire wound healing cascade. Its multi-functional and gentle formulation makes it a perfect companion treatment to DispersinB® Hydrogel, also part of the Kane Biotech antibiofilm wound care portfolio.
Watch Kane’s latest 2021 business update video series here.
About Kane Biotech
For more information, kanebiotech.com, or:
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
Keynote: State of the Cannabis Business Vertical
Asset Management â€“ Keeping Remote Devices Connected
Lone Worker Safety Solutions